title: Atorvastatin in dyslipidaemia of the nephrotic syndrome.
abstract: The combined dyslipidaemia that accompanies the nephrotic syndrome increases the cardiovascular risk and appears to worsen long-term renal function. Our aim was to determine the efficacy and safety of 10 mg atorvastatin in the control of dyslipidaemia in these patients. We carried out a prospective, open, 6 month study of 10 patients with primary or secondary nephrotic syndrome (proteinuria >3.5 g/day, hypoalbuminaemia, oedema and hyperlipidaemia). The changes in lipids and plasma lipoproteins were measured, as well as the safety profile (transaminases, creatine phosphokinase, fibrinogen and antithrombin III activity) and parameters of renal function. The addition of 10 mg atorvastatin daily for 6 months resulted in a 41% reduction in low density lipoprotein (LDL) cholesterol and 31% in triglycerides (both P < 0.05), and a 15% increase in high density lipoprotein (HDL) cholesterol (NS). The drug was well tolerated and there was no change in the safety profile or deterioration in renal function. In fact, the levels of proteinuria fell in all but one patient (6.2 +/- 2.6 vs 4.8 +/- 2.5 g/24 h; P < 0.05). Atorvastatin, at the above dose, and for the time used proved to be a safe drug that effectively reduced dyslipidaemia in patients with nephrotic syndrome.
authors.affiliation: Department of Internal Medicine, Nephrology and Lipid Unit, Hospital Clínico Universitario Virgen de la Victoria, Servicio Andaluz de Salud y Universidad de Málaga, Málaga, Spain. valdivielso@uma.es
authors.forename: Pedro
authors.initials: P
authors.lastname: Valdivielso
authors.forename: Manuel
authors.initials: M
authors.lastname: Moliz
authors.forename: Alfonso
authors.initials: A
authors.lastname: Valera
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Corrales
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Sanchez-Chaparro
authors.forename: Pedro
authors.initials: P
authors.lastname: Gonzalez-Santos
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000150:complications*; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin